Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference
20 Février 2024 - 2:42PM
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused
on transforming the lives of people with fluid overload, today
announced its planned activities at the upcoming Technology and
Heart Failure Therapeutics conference (THT 2024), which is produced
by the Cardiovascular Research Foundation (CRF), taking place March
4-6, in Boston.
Nuwellis will exhibit at booth #8, host a sponsored satellite
symposium and highlight two late-breaking clinical abstracts during
the conference. Events where Nuwellis and its Aquadex SmartFlow®
System will be featured at THT 2024 include:
Sponsored Satellite Symposium
- Title: Aquapheresis: New Technological and
Clinical Developments
- Presenters: Maria Rosa Costanzo, M.D., FHFSA,
Sean Pinney, M.D., FACC, FAST, FHFSA, Mark Hofmeyer, M.D., Aroti
Hegde, M.D.
- Date: Monday, March 4, 2024
- Time: 6:00-7:15 PM EST
- Location: Grand Ballroom A-B, Concourse
Level
Concurrent Session 1: Featured Lecture
- Title: Aquapheresis for Management of
Decompensated Heart Failure: A Re-appraisal of AVOID-HF
- Presenter: Sean Pinney, M.D., FACC, FAST,
FHFSA
- Date: Wednesday, March 6, 2024
- Time: 8:00-9:26 AM EST
- Location: Grand Ballroom C-E, Concourse
Level
Concurrent Session 1: Featured Late-Breaking Clinical
Science Abstracts III
- Title: AI Assisted Identification of Super
responders for Ultrafiltration can Reduce 90-Day Readmission Rates:
Evidence from AVOID-HF Trial
- Presenter: Oguz Akbilgic, DBA, Ph.D.
- Date: Wednesday, March 6, 2024
- Time: 8:00-9:26 AM EST
- Location: Grand Ballroom C-E, Concourse
Level
THT is a premier destination for pioneering data and
comprehensive updates on heart failure treatments using medical
technology. The conference provides a forward-looking view of the
heart failure therapeutics pipeline, delving into the role of
emerging technologies like artificial intelligence and machine
learning in heart failure patient care.
About NuwellisNuwellis, Inc. (Nasdaq: NUWE) is
a medical technology company dedicated to transforming the lives of
patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
commercializing the Aquadex SmartFlow® system for ultrafiltration
therapy. Nuwellis is headquartered in Minneapolis, with a wholly
owned subsidiary in Ireland. For more information visit
www.nuwellis.com or visit us on LinkedIn or X.
About the Aquadex SmartFlow®
SystemThe Aquadex SmartFlow system delivers
clinically proven therapy using a simple, flexible and smart method
of removing excess fluid from patients suffering from hypervolemia
(fluid overload). The Aquadex SmartFlow system is indicated for
temporary (up to 8 hours) or extended (longer than 8 hours in
patients who require hospitalization) use in adult and pediatric
patients weighing 20 kg or more whose fluid overload is
unresponsive to medical management, including diuretics. All
treatments must be administered by a health care provider, within
an outpatient or inpatient clinical setting, under physician
prescription, both having received training in extracorporeal
therapies.
Forward-Looking StatementsCertain statements in
this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the new
market opportunities and anticipated growth in 2024 and beyond.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our ability to execute on our commercialization strategy, the
impact of the COVID-19 pandemic, the possibility that we may be
unable to raise sufficient funds necessary for our anticipated
operations, our post-market clinical data collection activities,
benefits of our products to patients, our expectations with respect
to product development and commercialization efforts, our ability
to increase market and physician acceptance of our products,
potentially competitive product offerings, intellectual property
protection, our ability to integrate acquired businesses, our
expectations regarding anticipated synergies with and benefits from
acquired businesses, and other risks and uncertainties described in
our filings with the SEC. Forward-looking statements speak only as
of the date when made. Nuwellis does not assume any obligation to
publicly update or revise any forward-looking statements, whether
due to new information, future events or otherwise.
CONTACTS
Investors:Vivian CervantesGilmartin
Groupir@nuwellis.com
Media:Dunia
CristanHealth+Commercedunia@healthandcommerce.com
Newellis (NASDAQ:NUWE)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Newellis (NASDAQ:NUWE)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024